title: Liver cancer: time to evolve trial design after everolimus failure.
abstract: Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease. Now, the trial EVOLVE-1 has shown a lack of benefit for everolimus in the second-line treatment setting.
authors.affiliation: HCC Translational Research Laboratory, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona, Institució Catalana de Recerca i Estudis Avançats, Rosselló 153, 08036 Barcelona, Spain.
authors.forename: Josep M
authors.initials: JM
authors.lastname: Llovet
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D000068338:Everolimus; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
references.citation: Lancet. 2012 Mar 31;379(9822):1245-55
references.pmid: 22353262
references.citation: Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11
references.pmid: 18929564
references.citation: Nat Rev Cancer. 2006 Sep;6(9):674-87
references.pmid: 16929323
references.citation: JAMA. 2014 Jul 2;312(1):57-67
references.pmid: 25058218
references.citation: Hepatology. 2003 Feb;37(2):429-42
references.pmid: 12540794
references.citation: J Hepatol. 2012 Apr;56(4):908-43
references.pmid: 22424438
references.citation: Nat Rev Clin Oncol. 2014 Feb;11(2):73-4
references.pmid: 24395088
references.citation: N Engl J Med. 2010 Oct 28;363(18):1693-703
references.pmid: 20979469
references.citation: Clin Cancer Res. 2014 Apr 15;20(8):2072-9
references.pmid: 24589894
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514